Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 63

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 63
---
 -ownedsubsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design -augmentedbiologics for age -relatedand other degenerative diseases and (iii) neurovascular intervention medical devices and systems distribution in Korea. OSR Holdings’ vision is to acquire and operate a portfolio of innovative health -carerelated companies globally. The telephone number for OSR Holdings is +82 31 948 9419 and the principal mailing address is Hoedong -gil37 -36, 3 FL, Paju, Gyeonggido, Republic of Korea 10881. From inception through June 30, 2024, OSR Holdings has incurred significant operating losses and negative cash flows from its operations. OSR Holdings’ operating losses were KRW 784.7 million and KRW 14.7 billion for the years ended December 31, 2022 and December 31, 2023, respectively and KRW 4.8 billion and KRW 8.8 billion for the six months ended June 30, 2023 and 2024, respectively. As of June 30, 2024, OSR Holdings had an accumulated deficit of KRW 21.14 billion. Following the Closing, OSR Holdings will be managed by New OSR Holdings and operated as a majority owned subsidiary of New OSR Holdings. Please see the section entitled “ Management Following the Business Combination” for further information. 23 Emerging Growth Company BLAC is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “ JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes -OxleyAct of 2002 (the “ Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have